Direct and neurohumoral cardiovascular effects of atrial natriuretic peptide

Robyn L. Woods, Judith R. Oliver, Paul I. Korner

Research output: Contribution to journalArticleResearchpeer-review

16 Citations (Scopus)

Abstract

We studied the hemodynamic changes produced in conscious, chronically instrumented rabbits during steady-state administration of atrial natriuretic peptide (ANP). We administered synthetic α-human ANP intravenously (i.v.) at progressively increasing doses of 1, 2, and 4 μg/min, each for 30 min. In different experiments in each rabbit, we determined the effects of the peptide under closed-loop conditions in the intact animal and the "direct" circulatory effects of the peptide after "total" blockade of the autonomic nervous system (TAB) and after combined neurohumoral blockade (NHB), where in addition the vascular effects of vasopressin and angiotensin II were also prevented. In intact rabbits, ANP produced a dose-related reduction in mean arterial pressure (MAP, - 3 to - 14%), which was entirely due to a fall in cardiac output (CO, - 14 to - 20%), and there was a small rise in total peripheral resistance (TPR 5-12%). Heart rate remained unchanged. In rabbits subjected to TAB and NHB, all hemodynamic effects of ANP were attenuated. There were dose-related falls in left and right atrial pressures which reached maxima of -3.3 ± 0.9 and -1.8 ± 0.2 mm Hg, respectively. There was a reversible rise in hematocrit, probably owing to a shift of ∼8% in blood volume. These effects occurred mainly through direct actions of the peptide, and there was no evidence of systemic vasodilatation. The magnitude of reflex autonomic effects appeared to be less than expected for the observed fall in MAP, suggesting that ANP also inhibited cardiovascular reflexes.

Original languageEnglish
Pages (from-to)177-185
Number of pages9
JournalJournal of Cardiovascular Pharmacology
Volume13
Issue number2
Publication statusPublished - 1989
Externally publishedYes

Keywords

  • Atrial natriuretic peptide
  • Blood pressure
  • Cardiac output
  • Cardiovascular
  • Conscious rabbit
  • Hemodynamics

Cite this

@article{3a5c509c1f32449ebaa1d23f42c137fe,
title = "Direct and neurohumoral cardiovascular effects of atrial natriuretic peptide",
abstract = "We studied the hemodynamic changes produced in conscious, chronically instrumented rabbits during steady-state administration of atrial natriuretic peptide (ANP). We administered synthetic α-human ANP intravenously (i.v.) at progressively increasing doses of 1, 2, and 4 μg/min, each for 30 min. In different experiments in each rabbit, we determined the effects of the peptide under closed-loop conditions in the intact animal and the {"}direct{"} circulatory effects of the peptide after {"}total{"} blockade of the autonomic nervous system (TAB) and after combined neurohumoral blockade (NHB), where in addition the vascular effects of vasopressin and angiotensin II were also prevented. In intact rabbits, ANP produced a dose-related reduction in mean arterial pressure (MAP, - 3 to - 14{\%}), which was entirely due to a fall in cardiac output (CO, - 14 to - 20{\%}), and there was a small rise in total peripheral resistance (TPR 5-12{\%}). Heart rate remained unchanged. In rabbits subjected to TAB and NHB, all hemodynamic effects of ANP were attenuated. There were dose-related falls in left and right atrial pressures which reached maxima of -3.3 ± 0.9 and -1.8 ± 0.2 mm Hg, respectively. There was a reversible rise in hematocrit, probably owing to a shift of ∼8{\%} in blood volume. These effects occurred mainly through direct actions of the peptide, and there was no evidence of systemic vasodilatation. The magnitude of reflex autonomic effects appeared to be less than expected for the observed fall in MAP, suggesting that ANP also inhibited cardiovascular reflexes.",
keywords = "Atrial natriuretic peptide, Blood pressure, Cardiac output, Cardiovascular, Conscious rabbit, Hemodynamics",
author = "Woods, {Robyn L.} and Oliver, {Judith R.} and Korner, {Paul I.}",
year = "1989",
language = "English",
volume = "13",
pages = "177--185",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams & Wilkins",
number = "2",

}

Direct and neurohumoral cardiovascular effects of atrial natriuretic peptide. / Woods, Robyn L.; Oliver, Judith R.; Korner, Paul I.

In: Journal of Cardiovascular Pharmacology, Vol. 13, No. 2, 1989, p. 177-185.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Direct and neurohumoral cardiovascular effects of atrial natriuretic peptide

AU - Woods, Robyn L.

AU - Oliver, Judith R.

AU - Korner, Paul I.

PY - 1989

Y1 - 1989

N2 - We studied the hemodynamic changes produced in conscious, chronically instrumented rabbits during steady-state administration of atrial natriuretic peptide (ANP). We administered synthetic α-human ANP intravenously (i.v.) at progressively increasing doses of 1, 2, and 4 μg/min, each for 30 min. In different experiments in each rabbit, we determined the effects of the peptide under closed-loop conditions in the intact animal and the "direct" circulatory effects of the peptide after "total" blockade of the autonomic nervous system (TAB) and after combined neurohumoral blockade (NHB), where in addition the vascular effects of vasopressin and angiotensin II were also prevented. In intact rabbits, ANP produced a dose-related reduction in mean arterial pressure (MAP, - 3 to - 14%), which was entirely due to a fall in cardiac output (CO, - 14 to - 20%), and there was a small rise in total peripheral resistance (TPR 5-12%). Heart rate remained unchanged. In rabbits subjected to TAB and NHB, all hemodynamic effects of ANP were attenuated. There were dose-related falls in left and right atrial pressures which reached maxima of -3.3 ± 0.9 and -1.8 ± 0.2 mm Hg, respectively. There was a reversible rise in hematocrit, probably owing to a shift of ∼8% in blood volume. These effects occurred mainly through direct actions of the peptide, and there was no evidence of systemic vasodilatation. The magnitude of reflex autonomic effects appeared to be less than expected for the observed fall in MAP, suggesting that ANP also inhibited cardiovascular reflexes.

AB - We studied the hemodynamic changes produced in conscious, chronically instrumented rabbits during steady-state administration of atrial natriuretic peptide (ANP). We administered synthetic α-human ANP intravenously (i.v.) at progressively increasing doses of 1, 2, and 4 μg/min, each for 30 min. In different experiments in each rabbit, we determined the effects of the peptide under closed-loop conditions in the intact animal and the "direct" circulatory effects of the peptide after "total" blockade of the autonomic nervous system (TAB) and after combined neurohumoral blockade (NHB), where in addition the vascular effects of vasopressin and angiotensin II were also prevented. In intact rabbits, ANP produced a dose-related reduction in mean arterial pressure (MAP, - 3 to - 14%), which was entirely due to a fall in cardiac output (CO, - 14 to - 20%), and there was a small rise in total peripheral resistance (TPR 5-12%). Heart rate remained unchanged. In rabbits subjected to TAB and NHB, all hemodynamic effects of ANP were attenuated. There were dose-related falls in left and right atrial pressures which reached maxima of -3.3 ± 0.9 and -1.8 ± 0.2 mm Hg, respectively. There was a reversible rise in hematocrit, probably owing to a shift of ∼8% in blood volume. These effects occurred mainly through direct actions of the peptide, and there was no evidence of systemic vasodilatation. The magnitude of reflex autonomic effects appeared to be less than expected for the observed fall in MAP, suggesting that ANP also inhibited cardiovascular reflexes.

KW - Atrial natriuretic peptide

KW - Blood pressure

KW - Cardiac output

KW - Cardiovascular

KW - Conscious rabbit

KW - Hemodynamics

UR - http://www.scopus.com/inward/record.url?scp=0024545592&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 177

EP - 185

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 2

ER -